Genetic Systems technology purchase
Executive Summary
Firm purchased from Cutter all rights to its Phase/research program for the production of therapeutic human monocional antibodies for hospital-acquired infections from gram negative bacteria. Two firms had previously agreed to undertake the research in October 1983. Under a separate agreement with the Cutter Group, Genetic Systems is developing human monoclonal antibodies to pseudomonas bacteria. Antibodies have bean transferred to Cutter for scale-up and clinical trials. Genetic Systems said it will receive a royalty on all saies of products for pseudomonas infections.